NCT06909604View on ClinicalTrials.gov

Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Breast Cancer
Interventions
RADIATION

HER2 expression of PET imaging

Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

North Sichuan Medical College

OTHER

lead

Peking University Cancer Hospital & Institute

OTHER